



COVID-19 and Pregnancy: Prevention and Control Strategies for Coronavirus in Women

Guest Editor:

Dr. Gianluca Straface

Division of Perinatal Medicine,
Abano Terme, Italy

Deadline for manuscript
submissions:

closed (31 January 2024)

Message from the Guest Editor

The novel severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2) began in Wuhan, China in December 2019. As of 17 March 2020, 153 countries had reported cases of infection caused by this virus, with Italy becoming the new epicentre. COVID-19 is a global public health emergency and could cause devastating health issues during pregnancy.

Interim COVID-19 guidelines for the effective counselling and education of pregnant women are currently available from the Center for Disease Control and Prevention (CDC) and the World Health Organization (WHO). Recommendations which were published following the COVID epidemic in Wuhan are also available from Chinese experts.

December 2019. At the same time, the fact that results from studies concerning COVID-19 infection in pregnant and lactating women are being published so quickly may be a limitation of any review of the literature.

More original studies regarding infected pregnant women are needed to establish totally evidence-based protocols of care for these patients.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com